• Schedule An Appointment
  • (855) 528-7322
  • Career Openings
  • Español 中國傳統的 简体中文
  • Locations
  • Care Team
  • Locations
  • Care Team
    • All Doctors
    • Medical Oncologists
    • Radiation Oncologists
    • Breast Surgeons
    • Surgical Oncologist
    • Support/Palliative
    • Behavioral Health
    • Registered Dietitian Nutritionists
    • Our APPs
  • Patients
    • Accepted Insurance
    • Appointments
    • Blood Disorders
    • Cancers
    • Carespace Portal
    • Fill my Prescription
    • Make A Payment
    • Mammography
    • Medical Marijuana
    • Patient Advocacy
    • Physical Therapy
    • Radiology
  • Professionals
    • Patient Referral
    • Clinical Trials
    • Our Research Center
    • Our Research Team
    • Career Opportunities
    • News & Events
    • NCCN Guidelines
  • Research
    • About Research
    • Common Questions
    • Study Participation
    • Our Research Center
    • Our Research Team
    • Clinical Trials
  • About
    • About Us
    • News & Updates
    • Our Leadership
    • Our Difference
    • Our Friends
    • Our Services
      • Medical Oncology
      • Radiation Oncology
      • Hematology
      • Fill My Prescription
      • Physical Therapy
      • Health & Wellness
      • Laboratory Testing
      • Personalized Medicine
      • Diagnostic Imaging
      • Other Services
    • Career Opportunities
    • Newsletters

1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors

Condition: Solid Tumors

Sponsor: Boehringer Ingelheim

Full Title
Protocol 1403-0002: A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors

Study Treatment
MDM2 inhibitor BI 907828 + anti PD-1 antibody ezabenlimab

Eligibility/Info
Cohort 1: TP53 wild type soft tissue sarcoma (including liposarcoma excluding dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, synovial sarcoma, leiomyosarcoma)
Cohort 2: MDM2 amplified, TP53 wild type non-small cell lung cancer, gastric adenocarcinoma, urothelial carcinoma, biliary tract carcinoma

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.


Go To Trial Homepage

Call Us

(855) 528-7322

Contact us today to request an appointment.

Virtual & Telemedicine available.

Request Appointment

COVID-19 - Information

Learn more news and information related to COVID-19.

Learn More

Patient Links

  • Make An Appointment
  • Make A Payment
  • Fill My Prescription
  • Accepted Insurance
  • Medical Marijuana
  • Appointment Information
  • Physical Therapy
  • Patient Advocacy
  • Carespace Portal
  • Cancer Information

About

  • Our Story
  • Our Care Team
  • Locations
  • Careers & Job Openings
  • Newsletters
  • What Is Cancer?
  • What Are Blood Disorders?
  • What Is Oncology?
  • What Is Hematology?

Research

  • About Research
  • Common Questions
  • Study Participation
  • Our Research Center
  • Our Research Team
  • Clinical Trials
  • Observational Studies
  • Cancer Resources
  • Blood Disorder Resources

Contact Us


info@nycancer.com

  • Terms and Conditions
  • Privacy Policy
  • HIPAA and Compliance
  • Healthix
© 2023 NYCancer.com